Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC0OKA)

• Drug Name: (+/-)-7-methoxy-2-phenylchroman-4-one Drug Info
• Synonyms: 7-methoxy-2-phenylchroman-4-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2825024
  TTD Drug ID: DMC0OKA

Molecule-Related Drug Atlas

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[3]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[4]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[4]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[5]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[6]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[7]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[9]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[10]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[8]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[11]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[12]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[13]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[14]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[15]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[16]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[17]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[18]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[19]
Budipine	DMODHQI	Migraine	8A80	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[2]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[1]

References

• [1] A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
• [2] New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
• [3] Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
• [4] Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
• [5] Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
• [6] Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
• [7] Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
• [8] Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
• [9] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
• [11] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [12] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [13] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [15] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [16] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [17] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [18] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [20] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.